%0 English Abstract
%T [Olimetastatic disease: Current status and perspectives in non-small cell lung cancer].
%A Berghmans T
%A Brandão M
%J Rev Mal Respir
%V 40
%N 8
%D 2023 Oct
%M 37500325
%F 0.714
%R 10.1016/j.rmr.2023.07.002
%X The concept of oligometastatic disease was first introduced in the late 1990s to describe an situation more or less midway between locally advanced tumours and multifocal metastatic cancer. Four concepts are currently used: synchronous oligometastatic disease, metachronous oligometastatic disease (or oligo-recurrence), oligo-persistence and oligo-progression. Some phase II studies, randomised or not, have validated this concept in non-small cell lung cancer (NSCLC) and suggest the interest of adding local ablative therapy to systemic treatment. That said, numerous questions remain, and the impact of this therapeutic approach in the framework of immunotherapies and targeted therapies has yet to be assessed. Which of these new treatments offer hope of significantly improved long-term survival in stage IV NSCLC? This article appraises current knowledge and therapeutic regarding oligometastatic NSCLC.